# Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction

> **NCT00757172** · PHASE2 · COMPLETED · sponsor: **Alliance for Clinical Trials in Oncology** · enrollment: 70 (actual)

## Conditions studied

- Adenocarcinoma of the Gastroesophageal Junction
- Esophageal Cancer

## Interventions

- **BIOLOGICAL:** panitumumab
- **DRUG:** cisplatin
- **DRUG:** docetaxel
- **PROCEDURE:** neoadjuvant therapy
- **PROCEDURE:** therapeutic conventional surgery
- **RADIATION:** radiation therapy

## Key facts

- **NCT ID:** NCT00757172
- **Lead sponsor:** Alliance for Clinical Trials in Oncology
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2009-01
- **Primary completion:** 2011-11
- **Final completion:** 2014-12
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2016-03-11

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00757172

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00757172, "Panitumumab, Docetaxel, Cisplatin, Radiation Therapy, and Surgery in Treating Patients With Newly Diagnosed, Locally Advanced Esophageal Cancer or Cancer of the Gastroesophageal Junction". Retrieved via AI Analytics 2026-06-03 from https://api.ai-analytics.org/clinical/NCT00757172. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*